
|Videos|December 6, 2021
Dr. Siddiqui on first-line treatments for bladder cancer
Author(s)Urology Times staff
“This category of therapeutic is fairly well-tolerated; safe to give,” says Mohummad M. Siddiqui MD.
Advertisement
In this video, Mohummad M. Siddiqui, MD, discusses the main takeaways concerning the bladder cancer therapeutics durvalumab (Imfinzi)/atezolizumab (Tecentriq) and pembrolizumab (Keytruda)/atezolizumab, which were topics focused on during the bladder cancer course presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Siddiqui is an associate professor of surgery and director of urologic oncology and robotic surgery at the University of Maryland, Baltimore.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA updates in urology: May 2026
4
FDA approves cefepime and zidebactam for complicated UTI
5











